Puridify, a London, UK-based a bioprocessing company, closed a £2.2m Series A funding round.
Backers included existing investors Imperial Innovations, SR One, and UCL Business.
The company, which has raised £8m in total including grant funding, intends to use the funds to commercialize its platform.
Formed in 2013 as a spin-out from University College London and led by Dr Oliver Hardick, CEO, Puridify is developing a platform purification technology, FibroSelect, for industrial biomolecule manufacture. Advanced during a collaborative research project between the Advanced Centre for Biochemical Engineering, UCL and the Science & Technology Facilities Council, the company’s platform is suited to support biologics manufacturing industry’s increasing interest in single use and demand for smaller, more flexible manufacturing facilities that can produce multiple products.